Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Apr;105(4):980–984. doi: 10.1111/j.1476-5381.1992.tb09088.x

Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine.

R G Pertwee 1, L A Stevenson 1, D B Elrick 1, R Mechoulam 1, A D Corbett 1
PMCID: PMC1908724  PMID: 1324060

Abstract

1. The psychoactive cannabinoids (-)-delta 9-tetrahydrocannabinol ((-)-delta 9-THC) and the 1,1-dimethyl-heptyl homologue of (-)-11-hydroxy-delta 8-tetrahydrocannabinol ((-)-DMH) both inhibited electrically-evoked contractions of the mouse isolated vas deferens and the myenteric plexus-longitudinal muscle preparation of the guinea-pig small intestine. 2. Concentrations of (-)-delta 9-THC and (-)-DMH that decreased twitch heights by 50% were 6.3 and 0.15 nM respectively in the mouse vas deferens and 60 nM and 1.4 nM respectively in the myenteric plexus preparation. (-)-DMH was about 40 times more potent than (-)-delta 9-THC in both preparations, supporting the notion that their mode of action in each tissue is the same. 3. The psychically inactive cannabinoid, (+)-DMH, had no inhibitory effect in the mouse vas deferens at a concentration of 30 nM, showing it to be at least 1000 times less potent than (-)-DMH. In the myenteric plexus preparation, (+)-DMH was about 500 times less potent than its (-)-enantiomer. 4. The inhibitory effects of sub-maximal concentrations of (-)-delta 9-THC were not attenuated by 300 nM naloxone. 5. The findings that (-)-delta 9-THC and (-)-DMH are highly potent as inhibitors of the twitch response of the mouse vas deferens and guinea-pig myenteric plexus preparation and that DMH shows considerable stereoselectivity suggest that the inhibitory effects of cannabinoids in these preparations are mediated by cannabinoid receptors.

Full text

PDF
980

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P. F., Jackson D. M., Chesher G. B., Malor R. Tolerance to the effect of delta9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity. Psychopharmacologia. 1975 Jul 23;43(1):31–36. doi: 10.1007/BF00437611. [DOI] [PubMed] [Google Scholar]
  2. Bidaut-Russell M., Devane W. A., Howlett A. C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem. 1990 Jul;55(1):21–26. doi: 10.1111/j.1471-4159.1990.tb08815.x. [DOI] [PubMed] [Google Scholar]
  3. Corbett A. D., Gillan M. G., Kosterlitz H. W., McKnight A. T., Paterson S. J., Robson L. E. Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Br J Pharmacol. 1984 Sep;83(1):271–279. doi: 10.1111/j.1476-5381.1984.tb10143.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Devane W. A., Dysarz F. A., 3rd, Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988 Nov;34(5):605–613. [PubMed] [Google Scholar]
  5. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991 Feb;11(2):563–583. doi: 10.1523/JNEUROSCI.11-02-00563.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932–1936. doi: 10.1073/pnas.87.5.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hillard C. J., Pounds J. J., Boyer D. R., Bloom A. S. Studies of the role of membrane lipid order in the effects of delta 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther. 1990 Mar;252(3):1075–1082. [PubMed] [Google Scholar]
  8. Hughes J., Kosterlitz H. W., Leslie F. M. Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics. Br J Pharmacol. 1975 Mar;53(3):371–381. doi: 10.1111/j.1476-5381.1975.tb07373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Järbe T. U., Hiltunen A. J., Mechoulam R. Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther. 1989 Sep;250(3):1000–1005. [PubMed] [Google Scholar]
  10. Kosterlitz H. W., Lydon R. J., Watt A. J. The effects of adrenaline, noradrenaline and isoprenaline on inhibitory alpha- and beta-adrenoceptors in the longitudinal muscle of the guinea-pig ileum. Br J Pharmacol. 1970 Jun;39(2):398–413. doi: 10.1111/j.1476-5381.1970.tb12903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leslie F. M. Methods used for the study of opioid receptors. Pharmacol Rev. 1987 Sep;39(3):197–249. [PubMed] [Google Scholar]
  12. Little P. J., Compton D. R., Mechoulam R., Martin B. R. Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav. 1989 Mar;32(3):661–666. doi: 10.1016/0091-3057(89)90014-2. [DOI] [PubMed] [Google Scholar]
  13. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 Aug 9;346(6284):561–564. doi: 10.1038/346561a0. [DOI] [PubMed] [Google Scholar]
  14. Pacheco M., Childers S. R., Arnold R., Casiano F., Ward S. J. Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther. 1991 Apr;257(1):170–183. [PubMed] [Google Scholar]
  15. Paton W. D., Zar M. A. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol. 1968 Jan;194(1):13–33. doi: 10.1113/jphysiol.1968.sp008392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pertwee R. G., Wickens A. P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology. 1991 Mar;30(3):237–244. doi: 10.1016/0028-3908(91)90150-a. [DOI] [PubMed] [Google Scholar]
  17. Roth S. H. Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol. 1978 Dec;56(6):968–975. doi: 10.1139/y78-154. [DOI] [PubMed] [Google Scholar]
  18. Roth S. H., Williams P. J. The non-specific membrane binding properties of delta9-tetrahydrocannabinol and the effects of various solubilizers. J Pharm Pharmacol. 1979 Apr;31(4):224–230. doi: 10.1111/j.2042-7158.1979.tb13484.x. [DOI] [PubMed] [Google Scholar]
  19. Thomas B. F., Compton D. R., Martin B. R. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther. 1990 Nov;255(2):624–630. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES